Open-Label Pilot Study of Levetiracetam (Keppra) for the Treatment of Chorea in Huntington’s Disease

Kelly L. Sullivan; Theresa A. Zesiewicz; Robert A. Hauser; Juan Sanchez-Ramos

doi:10.1002/mds.21061

Open-Label Pilot Study of Levetiracetam (Keppra) for the Treatment of Chorea in Huntington’s Disease

Kelly L. Sullivan, Theresa A. Zesiewicz, Robert A. Hauser, Juan Sanchez-Ramos

Biostatistics, Epidemiology, & Environmental Health Sciences

University of South Florida

Research output: Contribution to journal › Article › peer-review

24 Scopus citations

Abstract

<div class="line" id="line-5"> The objective of this study is to evaluate the tolerability and preliminary efficacy of levetiracetam (LEV) in reducing chorea in Huntington's disease (HD) patients in a prospective open&hyphen;label pilot study. Nine HD patients with chorea were treated with LEV in doses up to 3,000 mg/day for up to 48 days. The primary endpoint measure was the Unified Huntington's Disease Rating Scale (UHDRS) chorea subscore. The mean dose (±SD) of LEV at endpoint was 2,583.3 ± 1,020.6 mg/day. Mean UHDRS chorea score decreased from 12.6 ± 3.0 at baseline to 6.7 ± 4.3 at endpoint (P = 0.01). There was no significant change in UHDRS total motor scores (38.8 ± 11.4 at baseline and 33.6 ± 26.7 at endpoint; P = 0.24). Somnolence contributed to a 33% drop&hyphen;out rate, and 3 patients developed Parkinsonism. Results of this open label study suggest that LEV may be efficacious in reducing chorea in HD patients.</div>

Original language	American English
Journal	Movement Disorder
Volume	21
DOIs	https://doi.org/10.1002/mds.21061
State	Published - Nov 21 2006

Keywords

Chorea
Huntington's Disease
Keppra
Levetiracetem

DC Disciplines

Public Health

Access to Document

10.1002/mds.21061License: Unspecified

Cite this

@article{56d477eee6aa4a89bbc8deb459357356,

title = "Open-Label Pilot Study of Levetiracetam (Keppra) for the Treatment of Chorea in Huntington{\textquoteright}s Disease",

abstract = " The objective of this study is to evaluate the tolerability and preliminary efficacy of levetiracetam (LEV) in reducing chorea in Huntington's disease (HD) patients in a prospective open&hyphen;label pilot study. Nine HD patients with chorea were treated with LEV in doses up to 3,000 mg/day for up to 48 days. The primary endpoint measure was the Unified Huntington's Disease Rating Scale (UHDRS) chorea subscore. The mean dose (±SD) of LEV at endpoint was 2,583.3 ± 1,020.6 mg/day. Mean UHDRS chorea score decreased from 12.6 ± 3.0 at baseline to 6.7 ± 4.3 at endpoint (P = 0.01). There was no significant change in UHDRS total motor scores (38.8 ± 11.4 at baseline and 33.6 ± 26.7 at endpoint; P = 0.24). Somnolence contributed to a 33% drop&hyphen;out rate, and 3 patients developed Parkinsonism. Results of this open label study suggest that LEV may be efficacious in reducing chorea in HD patients.",

keywords = "Chorea, Huntington's Disease, Keppra, Levetiracetem",

author = "Sullivan, {Kelly L.} and Zesiewicz, {Theresa A.} and Hauser, {Robert A.} and Juan Sanchez-Ramos",

note = "Enter your email address below. If your address has been previously registered, you will receive an email with instructions on how to reset your password. If you don't receive an email, you should register as a new user",

year = "2006",

month = nov,

day = "21",

doi = "10.1002/mds.21061",

language = "American English",

volume = "21",

journal = "Movement Disorder",

}

TY - JOUR

T1 - Open-Label Pilot Study of Levetiracetam (Keppra) for the Treatment of Chorea in Huntington’s Disease

AU - Sullivan, Kelly L.

AU - Zesiewicz, Theresa A.

AU - Hauser, Robert A.

AU - Sanchez-Ramos, Juan

N1 - Enter your email address below. If your address has been previously registered, you will receive an email with instructions on how to reset your password. If you don't receive an email, you should register as a new user

PY - 2006/11/21

Y1 - 2006/11/21

N2 - The objective of this study is to evaluate the tolerability and preliminary efficacy of levetiracetam (LEV) in reducing chorea in Huntington's disease (HD) patients in a prospective open&hyphen;label pilot study. Nine HD patients with chorea were treated with LEV in doses up to 3,000 mg/day for up to 48 days. The primary endpoint measure was the Unified Huntington's Disease Rating Scale (UHDRS) chorea subscore. The mean dose (±SD) of LEV at endpoint was 2,583.3 ± 1,020.6 mg/day. Mean UHDRS chorea score decreased from 12.6 ± 3.0 at baseline to 6.7 ± 4.3 at endpoint (P = 0.01). There was no significant change in UHDRS total motor scores (38.8 ± 11.4 at baseline and 33.6 ± 26.7 at endpoint; P = 0.24). Somnolence contributed to a 33% drop&hyphen;out rate, and 3 patients developed Parkinsonism. Results of this open label study suggest that LEV may be efficacious in reducing chorea in HD patients.

AB - The objective of this study is to evaluate the tolerability and preliminary efficacy of levetiracetam (LEV) in reducing chorea in Huntington's disease (HD) patients in a prospective open&hyphen;label pilot study. Nine HD patients with chorea were treated with LEV in doses up to 3,000 mg/day for up to 48 days. The primary endpoint measure was the Unified Huntington's Disease Rating Scale (UHDRS) chorea subscore. The mean dose (±SD) of LEV at endpoint was 2,583.3 ± 1,020.6 mg/day. Mean UHDRS chorea score decreased from 12.6 ± 3.0 at baseline to 6.7 ± 4.3 at endpoint (P = 0.01). There was no significant change in UHDRS total motor scores (38.8 ± 11.4 at baseline and 33.6 ± 26.7 at endpoint; P = 0.24). Somnolence contributed to a 33% drop&hyphen;out rate, and 3 patients developed Parkinsonism. Results of this open label study suggest that LEV may be efficacious in reducing chorea in HD patients.

KW - Chorea

KW - Huntington's Disease

KW - Keppra

KW - Levetiracetem

UR - https://doi.org/10.1002/mds.21061

U2 - 10.1002/mds.21061

DO - 10.1002/mds.21061

M3 - Article

VL - 21

JO - Movement Disorder

JF - Movement Disorder

ER -

Open-Label Pilot Study of Levetiracetam (Keppra) for the Treatment of Chorea in Huntington’s Disease

Abstract

Keywords

DC Disciplines

Access to Document

Other files and links

Fingerprint

Cite this